Morgan Stanley raised the firm’s price target on Merck (MRK) to $102 from $100 and keeps an Equal Weight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Moderately bullish activity in Merck with shares up 1.44%
- Largest borrow rate increases among liquid names
- Medicenna Therapeutics presents updated clinical data on MDNA11
- Merck price target raised to $120 from $100 at HSBC
- Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’